$CARM
Carisma Therapeutics Inc Stock $carm

$carm Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000148500323000119 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$4.289M	$3.800M	$40.00M
YoY Change		-90.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.324M	$6.620M	$8.141M
YoY Change	3.45%	-18.68%	-6.41%
% of Gross Profit
Research & Development	$19.42M	$19.55M	$2.931M
YoY Change	1922.4%	567.04%	-40.99%
% of Gross Profit
Depreciation & Amortization	$717.0K	$700.0K	$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses	$26.74M	$26.17M	$20.22M
YoY Change	232.57%	29.44%	-132.04%
Operating Profit		-$22.34M	$19.78M
YoY Change		-212.96%	-68.66%
Interest Expense	$1.295M	$941.0K	-$908.0K
YoY Change	-30.0%	-203.63%
% of Operating Profit			-4.59%
Other Income/Expense, Net			$676.0K
YoY Change			67500.0%
Pretax Income	-$21.16M	-$21.40M	$20.46M
YoY Change	179.46%	-204.61%	-67.59%
Income Tax	-$197.0K	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$20.96M	-$21.40M	$20.46M
YoY Change	176.86%	-204.62%	-71.46%
Net Earnings / Revenue	-488.65%	-563.24%	51.14%
Basic Earnings Per Share		-$0.53	$0.10
Diluted Earnings Per Share	-$0.52	-$0.53	$0.10
COMMON SHARES
Basic Shares Outstanding	40.36M shares	40.28M shares	199.5M shares
Diluted Shares Outstanding		40.29M shares	200.9M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$77.61M	$94.10M	$177.5M
YoY Change	-53.5%	-47.0%	1.31%
Cash & Equivalents	$77.61M	$83.13M	$71.11M
Short-Term Investments	$0.00	$11.00M	$106.4M
Other Short-Term Assets	$2.866M	$3.400M	$527.0K
YoY Change	-86.61%	545.16%	-97.82%
Inventory
Prepaid Expenses
Receivables			$0.00
Other Receivables			$14.30M
Total Short-Term Assets	$80.47M	$97.57M	$192.4M
YoY Change	-57.46%	-49.28%	-4.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.937M	$7.379M	$0.00
YoY Change			-100.0%
Goodwill			$0.00
YoY Change			-100.0%
Intangibles			$0.00
YoY Change			-100.0%
Long-Term Investments			$7.336M
YoY Change
Other Assets	$146.0K	$200.0K	$0.00
YoY Change			-100.0%
Total Long-Term Assets	$9.083M	$9.219M	$7.366M
YoY Change	30176.67%	25.16%	-79.07%
TOTAL ASSETS
Total Short-Term Assets	$80.47M	$97.57M	$192.4M
Total Long-Term Assets	$9.083M	$9.219M	$7.366M
Total Assets	$89.55M	$106.8M	$199.7M
YoY Change	-52.66%	-46.53%	-15.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.933M	$2.409M	$514.0K
YoY Change	218.98%	368.68%	-86.85%
Accrued Expenses	$7.662M	$7.026M	$33.80M
YoY Change	-74.15%	-79.21%	312.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$544.0K	$500.0K
YoY Change
Total Short-Term Liabilities	$15.91M	$12.95M	$34.70M
YoY Change	-48.66%	-62.67%	175.49%
LONG-TERM LIABILITIES
Long-Term Debt	$328.0K	$500.0K	$0.00
YoY Change
Other Long-Term Liabilities	$926.0K	$1.176M	$0.00
YoY Change	-11.05%
Total Long-Term Liabilities	$926.0K	$1.176M	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.91M	$12.95M	$34.70M
Total Long-Term Liabilities	$926.0K	$1.176M	$0.00
Total Liabilities	$63.02M	$60.49M	$34.70M
YoY Change	103.4%	74.34%	-53.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$245.1M	-$224.1M	-$328.6M
YoY Change	-27.08%	-31.79%	1.04%
Common Stock	$40.00K	$40.00K	$202.0K
YoY Change	-80.2%	-80.2%	1.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.53M	$46.30M	$165.0M
YoY Change
Total Liabilities & Shareholders Equity	$89.55M	$106.8M	$199.7M
YoY Change	-52.66%	-46.53%	-15.25%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$20.96M	-$21.40M	$20.46M
YoY Change	176.86%	-204.62%	-71.46%
Depreciation, Depletion And Amortization	$717.0K	$700.0K	$0.00
YoY Change			-100.0%
Cash From Operating Activities	-$16.10M	-$21.00M	$23.65M
YoY Change	-698.4%	-188.78%	-261.34%
INVESTING ACTIVITIES
Capital Expenditures	$562.0K	$190.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$11.00M	$30.00M	-$24.64M
YoY Change	-81.59%	-221.76%
Cash From Investing Activities	$10.44M	$29.81M	-$24.64M
YoY Change	-82.53%	-220.99%	-54851.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	100.0K	-2.030M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-16.10M	-21.00M	23.65M
Cash From Investing Activities	10.44M	29.81M	-24.64M
Cash From Financing Activities	100.0K	-2.030M	0.000
Net Change In Cash	-5.559M	6.780M	-983.0K
YoY Change	-108.9%	-789.73%	-104.06%
FREE CASH FLOW
Cash From Operating Activities	-$16.10M	-$21.00M	$23.65M
Capital Expenditures	$562.0K	$190.0K
Free Cash Flow	-$16.66M	-$21.19M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4822000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	30000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2023Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	146000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	4111000	usd
CY2023Q3	us-gaap	Assets Assets	106784000	usd
CY2022Q4	us-gaap	Assets Assets	72153000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2409000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1728000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7026000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10361000	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1185000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2459000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	856000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3437000	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	532000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1162000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	943000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	523000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	12951000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19670000	usd
CY2023Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	45000000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	45000000	usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	33717000	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5739000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	891000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	976000	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	468000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	872000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1176000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1041000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	60486000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	107015000	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	40000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	270029000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1197000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	373000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-41000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-224144000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-158223000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	46298000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-157065000	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	0	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	14395000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	46298000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-142670000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	106784000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72153000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3827000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2578000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10630000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6103000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15557000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54710000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38536000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6620000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3772000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22201000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8407000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	26171000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	19329000	usd
	us-gaap	Operating Expenses OperatingExpenses	76911000	usd
	us-gaap	Operating Expenses OperatingExpenses	46943000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22344000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16751000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-66281000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40840000	usd
CY2023Q3	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	usd
CY2022Q3	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-668000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-84000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-1369000	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	941000	usd
CY2022Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-908000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	641000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2278000	usd
CY2022Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-18327000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21403000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-18327000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65921000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-44487000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.11
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31209904	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31209904	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21403000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-18327000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65921000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-44487000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	108000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	37000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	414000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-160000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21295000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18290000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-65507000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44647000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	8700885	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	107808000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-142670000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	265000	usd
CY2023Q1	carm	Other Comprehensive Income Loss Marketable Securities Gain Loss After Adjustment And Tax OtherComprehensiveIncomeLossMarketableSecuritiesGainLossAfterAdjustmentAndTax	177000	usd
CY2023Q1	carm	Stock Issued During Period Values Preclosure Financing Transaction StockIssuedDuringPeriodValuesPreclosureFinancingTransaction	30640000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	42447000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	72044000	usd
CY2023Q1	carm	Reclassifications Of Temporary To Permanent Equity Shares ReclassificationsOfTemporaryToPermanentEquityShares	-8700885	shares
CY2023Q1	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-107808000	usd
CY2023Q1	carm	Stock Issued During Period Shares Conversion Of Convertible Preferred Stock And Non Controlling Interests Upon Merger StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger	107809000	usd
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11005000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	27802000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3428000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2596000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	97565000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	54592000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7379000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8628000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1664000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	107808000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40304436	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40304436	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2217737	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2217737	shares
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19551000	usd
CY2023Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-21403000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-65724000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-44487000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	197000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.37
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-21.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-21.14
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2189265	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2189265	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2104105	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2104105	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	86070000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	52000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	330000	usd
CY2023Q2	carm	Other Comprehensive Income Loss Marketable Securities Gain Loss After Adjustment And Tax OtherComprehensiveIncomeLossMarketableSecuritiesGainLossAfterAdjustmentAndTax	129000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-19876000	usd
CY2023Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	66705000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	40000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	848000	usd
CY2023Q3	carm	Other Comprehensive Income Loss Marketable Securities Gain Loss After Adjustment And Tax OtherComprehensiveIncomeLossMarketableSecuritiesGainLossAfterAdjustmentAndTax	108000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-21403000	usd
CY2023Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	46298000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	8700885	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	107808000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-81784000	usd
CY2022Q1	carm	Other Comprehensive Income Loss Marketable Securities Gain Loss After Adjustment And Tax OtherComprehensiveIncomeLossMarketableSecuritiesGainLossAfterAdjustmentAndTax	-158000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	58000	usd
CY2022Q2	carm	Other Comprehensive Income Loss Marketable Securities Gain Loss After Adjustment And Tax OtherComprehensiveIncomeLossMarketableSecuritiesGainLossAfterAdjustmentAndTax	-39000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-14848000	usd
CY2022Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	8700885	shares
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	107808000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-107994000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	88000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	88000	usd
CY2022Q3	carm	Other Comprehensive Income Loss Marketable Securities Gain Loss After Adjustment And Tax OtherComprehensiveIncomeLossMarketableSecuritiesGainLossAfterAdjustmentAndTax	37000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-18327000	usd
CY2022Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	8700885	shares
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	107808000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-126108000	usd
	us-gaap	Profit Loss ProfitLoss	-65921000	usd
	us-gaap	Profit Loss ProfitLoss	-44487000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2115000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1188000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1443000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	235000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4066000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2895000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1283000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1995000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-84000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-1369000	usd
	carm	Accretion On Marketable Securities AccretionOnMarketableSecurities	741000	usd
	carm	Accretion On Marketable Securities AccretionOnMarketableSecurities	0	usd
	carm	Noncash Interest Expense NoncashInterestExpense	117000	usd
	carm	Noncash Interest Expense NoncashInterestExpense	176000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-484000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1055000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	372000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1794000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3534000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4526000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1274000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	46230000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3574000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2882000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65080000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	11984000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	34460000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	84028000	usd
	carm	Payments For Proceeds From Marketable Securities PaymentsForProceedsFromMarketableSecurities	-97000000	usd
	carm	Payments For Proceeds From Marketable Securities PaymentsForProceedsFromMarketableSecurities	-42000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	571000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4341000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	61969000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46369000	usd
	carm	Cash Cash Equivalents And Restricted Cash Acquired In Reverse Recapitalization Financing Activities CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities	37903000	usd
	carm	Cash Cash Equivalents And Restricted Cash Acquired In Reverse Recapitalization Financing Activities CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities	0	usd
	carm	Payment Of Finance Costs Reverse Recapitalization Financing Activities PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities	5814000	usd
	carm	Payment Of Finance Costs Reverse Recapitalization Financing Activities PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30640000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1151000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	766000	usd
	carm	Proceeds From Failed Sale Leaseback Transaction ProceedsFromFailedSaleLeasebackTransaction	1183000	usd
	carm	Proceeds From Failed Sale Leaseback Transaction ProceedsFromFailedSaleLeasebackTransaction	505000	usd
	carm	Payment Of Finance Liability Failed Sale Leaseback Transaction PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction	628000	usd
	carm	Payment Of Finance Liability Failed Sale Leaseback Transaction PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction	50000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	146000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	35000000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	92000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	88000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	62079000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34777000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	58968000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	392000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24194000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28551000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83162000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28943000	usd
	us-gaap	Interest Paid Net InterestPaidNet	283000	usd
	us-gaap	Interest Paid Net InterestPaidNet	50000	usd
	carm	Noncash Or Part Noncash Acquisition Equity Assumed NoncashOrPartNoncashAcquisitionEquityAssumed	122204000	usd
	carm	Noncash Or Part Noncash Acquisition Equity Assumed NoncashOrPartNoncashAcquisitionEquityAssumed	0	usd
	us-gaap	Notes Reduction NotesReduction	42447000	usd
	us-gaap	Notes Reduction NotesReduction	0	usd
	carm	Noncash Or Part Noncash Unrealized Gain Loss On Marketable Securities NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities	414000	usd
	carm	Noncash Or Part Noncash Unrealized Gain Loss On Marketable Securities NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities	-160000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	908000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6437000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	2471000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	0	usd
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	3820000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	295000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	90000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-224100000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	94100000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	37873000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Marketable Securities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities	44588000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	1316000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant areas that require management’s estimates include the fair value of the Company’s common stock and the derivative liability prior to the Merger, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></div>
CY2023Q1	carm	Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash	30000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	3499000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	80308000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6515345	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16569784	shares
CY2023Q3	carm	Number Of Board Members NumberOfBoardMembers	7	seat
CY2023Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	8264000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	72044000	usd
CY2023Q3	carm	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3555000	usd
CY2022Q4	carm	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	4326000	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1186000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2100000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1792000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2809000	usd
CY2023Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	197000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	296000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	0	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1126000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7026000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10361000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	4322000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	3331000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	890000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	264000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	117000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	50000	usd
	carm	Finance Lease Cost FinanceLeaseCost	1007000	usd
	carm	Finance Lease Cost FinanceLeaseCost	314000	usd
	us-gaap	Lease Cost LeaseCost	5329000	usd
	us-gaap	Lease Cost LeaseCost	3645000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	10191000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.46
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2023Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2022Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.093
CY2023Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.090
CY2022Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.090
	us-gaap	Operating Lease Payments OperatingLeasePayments	4028000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	3319000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	117000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	50000	usd
	carm	Financing Cash Used In Finance Leases FinancingCashUsedInFinanceLeases	1151000	usd
	carm	Financing Cash Used In Finance Leases FinancingCashUsedInFinanceLeases	766000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	622000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	150000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	403000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	600000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	219000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	338000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	226000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	233000	usd
CY2023Q3	carm	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	423000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2126000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1088000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	379000	usd
CY2023Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	88000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1747000	usd
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	1000000	usd
CY2023Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	200000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3730608	shares
CY2023Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	8.21
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30600000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	5059338	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	35000000	usd
CY2023Q1	carm	Stock Issued During Period Shares Conversion Of Convertible Preferred Stock And Non Controlling Interests StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests	18872711	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	10374272	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3356937	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.01
	carm	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross	765223	shares
	carm	Share Based Compensation Arrangements By Share Based Payment Award Options Assumed In Merger Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice	27.94
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	49770	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.72
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	190000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2805152	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	87275	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.70
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	274922	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	23.52
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6515345	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.28
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10191000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3038911	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.71
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y21D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	8068000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	6515345	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.28
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y3M18D
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	848000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	88000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1443000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	235000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11700000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y9M18D
	carm	Tax Revenue Related To Collaboration And License Agreement With Related Party TaxRevenueRelatedToCollaborationAndLicenseAgreementWithRelatedParty	45000000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3800000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2600000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10600000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6100000	usd
CY2023Q3	carm	Revenue Remaining Performance Obligation Research And Development Amount RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount	52333000	usd
CY2023Q3	carm	Revenue Remaining Performance Obligation Option Rights Amount RevenueRemainingPerformanceObligationOptionRightsAmount	45000000	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	97333000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	47459000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
	carm	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	9356000	usd
	carm	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	52333000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-10630000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-6103000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	46185000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	46230000	usd
	carm	Tax Revenue Related To Collaboration And License Agreement With Related Party TaxRevenueRelatedToCollaborationAndLicenseAgreementWithRelatedParty	45000000.0	usd

Files In Submission

Name	View Source	Status
carm-20230930_cal.xml	Edgar Link	unprocessable
carm-20230930_def.xml	Edgar Link	unprocessable
0001485003-23-000119-index-headers.html	Edgar Link	pending
0001485003-23-000119-index.html	Edgar Link	pending
0001485003-23-000119.txt	Edgar Link	pending
0001485003-23-000119-xbrl.zip	Edgar Link	pending
carm-20230930.htm	Edgar Link	pending
carm-20230930.xsd	Edgar Link	pending
carm-20230930xexx311.htm	Edgar Link	pending
carm-20230930xexx312.htm	Edgar Link	pending
carm-20230930xexx321.htm	Edgar Link	pending
carm-20230930xexx322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
carm-20230930_pre.xml	Edgar Link	unprocessable
carm-20230930_lab.xml	Edgar Link	unprocessable
carm-20230930_htm.xml	Edgar Link	completed
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CARM
Carisma Therapeutics Inc Stock $carm

2023 Q4 Form 10-Q Financial Statement

#000148500323000119 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CARM Carisma Therapeutics Inc Stock $carm

2023 Q4 Form 10-Q Financial Statement

#000148500323000119 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CARM
Carisma Therapeutics Inc Stock $carm